Stay updated on Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The page's revision label was updated from v3.5.3 to v3.5.4, signaling a new version of the page. This appears to be a minor administrative update rather than a change to the study details or outcomes.
    Difference
    0.1%
    Check dated 2026-05-15T06:53:14.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    No Change Detected
  4. Check
    21 days ago
    Change Detected
    Summary
    The page reflects a minor update to the platform/UI release revision, moving from “Revision: v3.5.2” to “Revision: v3.5.3.” This represents a technical/version change rather than a change to the displayed study information.
    Difference
    0.0%
    Check dated 2026-04-24T06:32:47.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    Revision updated to v3.5.2 and the v3.5.0 revision was removed.
    Difference
    0.0%
    Check dated 2026-04-17T02:47:33.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    Revision: v3.5.0 added; Revision: v3.4.3 removed, indicating an update to the page’s revision history.
    Difference
    0.0%
    Check dated 2026-03-19T06:24:06.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3. The new version is now displayed.
    Difference
    0.0%
    Check dated 2026-03-12T02:16:06.000Z thumbnail image
  8. Check
    93 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the funding-related notice (Revision: v3.4.1); these changes do not modify the study details, eligibility criteria, or outcomes presented on the page.
    Difference
    0.4%
    Check dated 2026-02-11T14:15:47.000Z thumbnail image

Stay in the know with updates to Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.